ClinicalTrials.gg
CompletedNCT05799755MINTUpdated Oct 15, 2026Results posted

Myositis Interstitial Lung Disease Nintedanib Trial

A Phase 4 interventional study of Nintedanib and Placebo in Myositis Associated Interstitial Lund Disease (MA-ILD), sponsored by Rohit Aggarwal, MD. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Rohit Aggarwal, MD · Phase 4, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
7th of 11
62 · median 81
Started
2023
the only one that year
Phase 4
2 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Rohit Aggarwal, MD

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 10th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.

This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.

The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).

Read the detailed description

Participants enrolled in the study will receive either study drug or placebo for 12 weeks plus the participant's normal standard of care medication for the participant's disease. Placebo is an inactive substance that contains no medicine. Following the initial treatment phase, participants will receive the active study drug (nintedanib) for an additional 12-week period.

Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).

The original trial registration listed an outcome measure for change in non-primary L-PF scores from Week 12 to Week 24. This did not appear in the final SAP and was removed from the outcome measures list. Additionally, the outcome measure of "L-PF Total Score" was included in the approved SAP, however we were informed a Total Score was not to be generated from the Symptoms and Impacts module scores. L-PF Total Score was included in the SAP in error and was not analyzed.

03

Conditions studied

  • Myositis Associated Interstitial Lund Disease (MA-ILD)

Keywords

  • Myositis associated interstitial lung disease (Myositis ILD)
  • Interstitial Lung Disease (ILD)
  • Myositis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has provided written
  2. Approval from local treating physician (done at pre-screening only for remote patients as well as for local site patients not actively being managed at the local site).
  3. Subject lives in the United States
  4. Adult: Age ≥ 18 years
  5. Subject can speak, read, and understand English or Spanish
  6. Subject is willing and capable of performing all study procedures.
  7. Validity/repeatability of home spirometry confirmed by PFT lab technician/MD through telemedicine as per American Thoracic Society guidelines.
  8. Men and women of must agree to use 2 reliable methods of during the trial period.
  9. Clinical diagnosis of myositis or presence of one of the following myositis-specific or -associated autoantibodies).

    1. Anti-synthetase autoantibody (Anti-Jo-1, -PL-7, -PL-12, -EJ, -OJ, -KS, -Tyr, -Zo)
    2. Anti-MDA5, TIF1-gamma, Mi-2, NXP2/MJ, SAE, HMGCR, SRP
    3. Anti-PM/Scl, Ku, U1RNP, Ro5,2/60, or SSA (in absence of clinical diagnosis of systemic sclerosis or primary Sjogren syndrome).
  10. Fibrosing Interstitial Lung Disease (ILD):

    1. HRCT chest within 12 months of screening visit with fibrosing ILD (reticular changes, traction bronchiectasis, and/or honeycombing)
    2. No other identifiable cause of fibrosis
    3. The following co-existing features are expected and accepted: ground glass opacity, upper lung or peri-bronchovascular predominance, mosaic attenuation, air trapping, consolidation, and centrilobular nodules.
  11. Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of the screening visit.

    1. ≥10% relative decline in FVC% predicted (%pred)
    2. ≥5 but \<10% relative decline in FVC %pred with worsening dyspnea.
    3. ≥5 but \<10% relative decline in FVC %pred with worsening chest HRCT fibrotic changes
    4. Worsening dyspnea with worsening chest HRCT fibrosis
    5. Worsening dyspenea with FCV% \</= 70%
  12. Standard of care (SOC) therapy: (See: SOC and washout under section 6.2 for details)

    1. Allowable SOC includes a maximum of 2: 1 (GC) and 1 Non-GC immunosuppressive medication (IS) Or 2 Non-GC immunosuppressive medications.
    2. Allowable IS component of SOC regimen must have been started at least 12 weeks prior and be stable for at least 4 weeks before baseline visit.
    3. In case a patient is not on any of the SOC immunosuppression, patient can be enrolled if at least 2 SOC immunosuppression are either previously failed or had intolerance or are .
    4. Allowable GC component of SOC regimen must have been started at least 4 weeks prior and be stable for at least 2 weeks before baseline visit.
    5. Allowable IS and GC:

      Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 2,160 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) JAK inhibitors (tofacitinib max does 11 mg/day, upadacitinib max dose 15 mg/day, baricitinib max does 4 mg/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every > 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy. Orencia (max dose of 125 mg SQ once a week or 1 gm monthly IV infusion)

    6. Inhaled medication(s) for lung disease is allowed if started > 4 weeks before screening.

    Should remain stable throughout the study.

  13. Negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  1. Planned major surgical procedures within the trial period of 24 weeks.
  2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  3. Women of * not willing or able to use at least two highly effective methods of .

    1. For females of : use of highly effective contraception for at least 1 month before study drug administration and agreement to use such a method during study participation and for an additional 28 days after the end of study drug administration.
    2. For males of reproductive potential**: use of condoms or other methods to ensure effective contraception with a partner

    Highly effective contraception examples are:

    • An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, hormonally-impregnated intrauterine device (IUD), or nonhormonal IUD.
    • Abstinence
    • Condoms

      • A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.

        • A man is considered permanently sterile if a vasectomy has been performed.
  4. Severe lung disease is defined by the following within the last 6 months before the screening:

    1. FVC ≤40 percent predicted
    2. DLCO \<30% of percent predicted (corrected for )
    3. O2 requirement of ≥10 L at rest based on home oxygen prescription.
    4. Patient listed for lung transplant or actively going through lung transplant evaluation.
  5. Moderate to severe active muscle disease from myositis as per any one of the criteria:

    1. Creatine kinase (CK) > 2000 U/mL.
    2. Moderate to severe dermatomyositis rashes as per investigator evaluation (if rash present)
    3. Moderate to severe arthritis as per investigator evaluation
    4. Moderate to severe muscle weakness as per Sit to Stand 30 seconds of \< 7.
  6. History of or ongoing serious active, chronic, or recurrent infection within 4 weeks of screening
  7. Significant Pulmonary Hypertension (PH) is defined by any of the following:

    1. Current clinical diagnosis of moderate to severe PH or significant right heart failure.
    2. History of echocardiographic evidence of significant right heart failure or moderate to severe PH (TR jet >= 2.9 m/s and signs of right ventricle (RV) dysfunction; or TR jet > 3.4; or an right ventricle systolic pressure (RVSP) > 40-55 with evidence of RV strain or dysfunction; or RVSP > 55 regardless.
    3. History of right heart catheterization showing a cardiac index ≤ 2.2 l/min/m² or severity of pulmonary hypertension (mPAP) >40 millimeters of mercury (mmHg) with a pulmonary capillary wedge pressure (PCWP) \<15mmHg
    4. PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil).
  8. Increased bleeding risk, defined by any of the following:

    1. Patients who require

      • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin)
      • High dose antiplatelet therapy (>325mg acetylsalicylic acid or >75mg clopidogrel).
    2. History of hemorrhagic central nervous system (CNS) event within 12 months of screening.
    3. Any of the following within 3 months of screening:

      • Hemoptysis or hematuria
      • Active gastrointestinal (GI) bleeding or active GI ulcers.
    4. Coagulation parameters: (INR) >2, prolongation of prothrombin time (PT) and by >1.5 x at screening.
  9. History of a thrombotic event (including stroke and ) within 12 months of screening.
  10. Severe Cardiovascular disease, any of the following:

    1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of screening.
    2. Myocardial infarction or unstable cardiac angina within 6 months of screening.
  11. Patients with underlying chronic liver disease ( A, B, or C hepatic impairment).
  12. Known to the trial medication or its components (i.e. soya lecithin)
  13. Other diseases that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation (such as significant GI issues like irritable bowel syndrome, inflammatory bowel disease, recent abdominal surgery, diverticular disease), or significant other lung diseases (such as severe obstructive lung disease such as severe asthma or severe , etc.) or may put the patient at risk when participating in this trial.
  14. for a disease other than ILD \< 2.5 years (Investigator assessment).
  15. In the opinion of the investigator, any condition precluding participation and completion of the study, including active alcohol and drug abuse or patients not able to understand or follow trial procedures.
  16. Other therapy was received within 1 month or 6 half-lives (whichever was greater) before the screening visit.
  17. Current treatment with nintedanib or pirfenidone (taken the drug within 3 months of randomization or history of intolerance/side effects)
  18. Current or recent use of one or more of the following medications (See: SOC and washout under section 6.2 for details)

    1. Cyclophosphamide within 3 months of baseline.
    2. Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
    3. Anakinra within 1 week of baseline.
    4. Other biological agents such as tocilizumab, etc. within 4 weeks of baseline.
  19. Safety laboratory abnormality as any one of below

    1. Aspartate transferase (), alanine aminotransferase (ALT) > 1.5 x ULN at screening, unless deemed due to active myositis by investigator, in which case CK is also abnormally elevated and the ratio of AST or ALT by CK levels (adjusted as x ULN) should be \< 2.0 and gamma-glutamyl transferase \< 2.0 x ULN.
    2. > 1.5 x ULN at screening
    3. \<30 mL/min calculated by Cockcroft-Gault formula at screening.
    4. Hgb \< 9.0
    5. count \< 100,000/mm3
    6. White blood cells \< 3000/mm3

      -

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus Standard of Care, then Nintedanib plus Standard of Care

    Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.

    Drug: Nintedanib · Drug: Placebo · Drug: Standard of Care

  • Active comparator
    Nintedanib plus Standard of Care

    Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.

    Drug: Nintedanib · Drug: Standard of Care

Interventions

  • Nintedanib 150 mg BID

    Also known as: OFEV

  • DrugPlacebo

    Placebo comparator

  • DrugStandard of Care

    Patients may receive up to 2 standard-of-care immunosuppressants (IS): either 1 glucocorticoid (GC) + 1 non-GC IS, or 2 non-GC IS if not on GC. IS must be used ≥12 weeks (≥4 weeks for GC) with stable doses ≥4 weeks (≥2 weeks for GC) before screening. Allowed therapies and max doses: GC ≤20 mg/day, mycophenolate mofetil 3 g/day, mycophenolic acid 2160 mg/day, azathioprine 2.5 mg/kg/day, methotrexate 25 mg/week, tacrolimus 10 mg/day, cyclosporine 200 mg/day, leflunomide 20 mg/day, sulfasalazine 3 g/day, JAK inhibitors (tofacitinib 11 mg/day, upadacitinib 15 mg/day, baricitinib 4 mg/day), rituximab (1000 mg ×2 or 375 mg/m² weekly ×4 every \>4 months), Orencia 125 mg SQ weekly or 1 g IV monthly. IVIG/SQIG and hydroxychloroquine are allowed but not considered SOC IS therapy. Inhaled lung medications allowed if started \>4 weeks before screening and remain stable.

06

What researchers measure

Primary outcomes

  1. Change in Living With Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 12

Secondary outcomes

  1. Change in Living With Pulmonary Fibrosis Dyspnea Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 24

  2. Change in Living With Pulmonary Fibrosis Dyspnea Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Week 12 to week 24

  3. Change in Living With Pulmonary Fibrosis Cough Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 12

  4. Change in Living With Pulmonary Fibrosis Cough Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 24

  5. Change in Living With Pulmonary Fibrosis Energy Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 12

  6. Change in Living With Pulmonary Fibrosis Energy Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 24

  7. Change in Living With Pulmonary Fibrosis Symptoms Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 12

  8. Change in Living With Pulmonary Fibrosis Symptoms Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 24

  9. Change in Living With Pulmonary Fibrosis Impacts Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 12

  10. Change in Living With Pulmonary Fibrosis Impacts Score

    The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.

    Time frame: Baseline (week 0) to week 24

  11. Change in Immunosuppressive (IS) Regimen

    Percentage of patients requiring an increased dose or a change in their glucocorticoid (GC) / immunosuppression (IS) agent for clinical worsening/flare of MA-ILD

    Time frame: Baseline (Week 0) to week 12

  12. Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks

    FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 12

  13. Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks

    FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 12

  14. Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 24

  15. Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 24

  16. Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 12

  17. Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 12

  18. Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 24

  19. Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 24

  20. Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 12

  21. Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 24

  22. Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 12

  23. Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 24

  24. Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 12

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 12

  25. Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 24

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 24

  26. Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 12

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 12

  27. Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 24

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

    Time frame: Week 24

  28. Time to FVC (mL) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)

    FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.

    Time frame: Baseline (week 0) to 24 weeks

  29. Time to FVC (%) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)

    FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.

    Time frame: Baseline (week 0) to 24 weeks

  30. Time to Progression

    Defined as either time for event a, b or c. Event a. ≥ 10% decline in FVC (mL) or death or transplant. Event b. ILD worsening definition (per protocol) or death or transplant. Event c. non-elective hospitalization for ILD worsening/flare or death or lung transplant.

    Time frame: Baseline (week 0) to week 24

Other outcomes

  1. Validity of Forced Vital Capacity (FVC) in ml Measured by Home Spirometry

    Validity of FVC (mL) by home spirometry is measured as intraclass correlation coefficient with FVC (mL) obtained by gold standard clinic spirometry. Unsupervised home spirometry values taken +/- 7 days from the in-clinic spirometry dates were averaged to calculate observational values.

    Time frame: Baseline (week 0) to week 24

  2. Reliability of Forced Vital Capacity (FVC) in mL by Home Spirometry

    Reliability of FVC (mL) by home spirometry is measured as spearman correlation with FVC (mL) of test (baseline) and re-test (Week 12). Unsupervised home spirometry values taken +/- 7 days from the test and re-test dates were averaged to calculate observational values.

    Time frame: Baseline (week 0) to week 12

  3. Absolute Change in DLCO(%) From Baseline to 12 Weeks

    DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 12

  4. Relative Change in DLCO(%) From Baseline to 12 Weeks

    DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 12

  5. Absolute Change in DLCO(%) From Baseline to 24 Weeks

    DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 24

  6. Relative Change in DLCO(%) From Baseline to 24 Weeks

    DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 24

  7. Absolute Change in FEV1(mL) From Baseline to 12 Weeks

    FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 12

  8. Relative Change in FEV1(mL) From Baseline to 12 Weeks

    FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 12

  9. Absolute Change in FEV1(mL) From Baseline to 24 Weeks

    FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 24

  10. Relative Change in FEV1(mL) From Baseline to 24 Weeks

    FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 24

  11. Absolute Change in FEV1(%) From Baseline to 12 Weeks

    FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 12

  12. Relative Change in FEV1(%) From Baseline to 12 Weeks

    FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 12

  13. Absolute Change in FEV1(%) From Baseline to 24 Weeks

    FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

    Time frame: Baseline (week 0) to week 24

  14. Relative Change in FEV1(%) From Baseline to 24 Weeks

    FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

    Time frame: Baseline (week 0) to week 24

  15. Progression Free Survival

    Connective Tissue Disease (CTD)-ILD outcome as per Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT), which is defined as the occurrence of any of the following: death, lung transplant, FVC ≥10% decline, or FVC ≥5% decline with DLCO ≥15% decline. Clinical worsening is defined as death, lung transplant, new/worsening O2 requirement at rest (\>2L), non-elective hospitalization for ILD clinical worsening/flare, ILD worsening definition (per protocol), or out of protocol rescue medication for ILD clinical worsening/flare.

    Time frame: Weeks 12 and 24

  16. Steroid Use (Calculated Using Prednisone Dose Equivalents)

    Change of steroid dosage (mg/day) from baseline to follow up.

    Time frame: Weeks 12 and 24

  17. Change in Supplemental Oxygen Needs From Baseline to Week 12

    Change in supplemental oxygen requirement (L) from baseline to follow up.

    Time frame: Baseline (week 0) to 12 weeks

  18. Change in Supplemental Oxygen Needs From Baseline to Week 24

    Change in supplemental oxygen requirement (L) from baseline to follow up.

    Time frame: Baseline (week 0) to 24 weeks

  19. Patient Assessment of Change

    Patient Assessment of Change (also known as Patient Global Impression of Change): Overall Assessment of Change by Patient. Patient overall assessment of change in disease status from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.

    Time frame: Weeks 12 and 24

  20. Physician Assessment of Change

    Physician's overall assessment of change in disease status of the patient from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.

    Time frame: Weeks 12 and 24

  21. Changes in Sit to Stand Test From Baseline to Week 12

    Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.

    Time frame: Baseline (week 0) to 12 weeks

  22. Changes in Sit to Stand Test From Baseline to Week 24

    Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.

    Time frame: Baseline (week 0) to 24 weeks

  23. Change in High-Resolution Computed Tomography (HRCT) Chest From Baseline

    HRCT patterns will be analyzed using semi-quantitative and quantitative image based scoring to summarize an image as normal or abnormal. Change of summary status from baseline to follow up. Patterns include: Ground glass, Consolidation / Air Space, Mixed GGO/AS, Parenchymal Micronodules, Reticular Opacities, Linear Opacities or Septal Lines, Peribronchovascular Thickening, Honeycombing, and Traction Bronchiectasis.

    Time frame: Baseline (week 0) to 24 weeks

  24. Adverse Events (AEs) and Tolerance

    All AEs and tolerance event will be compared between treatment arms * Percentage of subjects who discontinue study drug * Patients with any AEs * Patients with Serious Adverse Event (SAE)s (includes patient with AE of special interest) * Patients with AEs of special interest (gastrointestinal perforation and hepatic injury)

    Time frame: Baseline (week 0) to week 24 plus 28 day follow-up

  25. Rate of Patient Recruitment, Enrollment, Screen Failure, and Dropout Rates Between the Local Sites and the Remote Site of Physician Referred Patients.

    Compare the participant recruitment, enrollment, screen failure and drop out rates between participants recruited through local clinical trial site vs. remote clinical trial site physician referrals. Not all participants were enrolled, and not all participants were physician referrals. 57 of 62 enrolled participants were physician referrals. 44 of 49 randomized participants were physician referrals.

    Time frame: Patient recruitment to randomization. Median of 51 days from recruitment to randomization. Randomization occurred at baseline.

07

Results

Posted Oct 15, 2026
Limitations and caveats
A limitation of the study is small sample size that affects statistical power to determine statistical significance in differences between treatment arms.

Participant flow

Participants were across 11 clinical sites and 1 remote site (the University of Pittsburgh only). The University of Pittsburgh also served as a clinical site and the coordinating center. Participants enrolled and randomized from the 11 clinical sites are referred to as local site patients, and patients enrolled and randomized from the University of Pittsburgh remote site are referred to as remote site patients. Remote patients were solely managed through the University of Pittsburgh.

Nintedanib Versus Placebo
Participant flow — Nintedanib Versus Placebo
MilestonePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Started2425
Completed2222
Not completed23
Open-Label Nintedanib
Participant flow — Open-Label Nintedanib
MilestonePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Started2222
Completed2220
Not completed02

Outcome measures

PrimaryChange in Living With Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Actual Baseline17.1 ± 18.820.9 ± 16.0
Change Baseline to 12 Weeks0.6 ± 10.62.1 ± 11.4
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.624 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.666 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.679 (Significance threshold of 0.05.) · Mean difference (net): 1.44 · 95% CI -5.42 to 8.3Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.864 (Significance threshold of 0.05.) · Mean difference (net): 0.59 · 95% CI -6.17 to 7.34Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Dyspnea Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Dyspnea Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Dyspnea Score0.3 ± 10.32.8 ± 16.9
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.644 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.564 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.485 (Significance threshold of 0.05.) · Mean difference (net): 2.5 · 95% CI -4.53 to 9.53Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.644 (Significance threshold of 0.05.) · Mean difference (net): 1.63 · 95% CI -5.32 to 8.58Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Dyspnea Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Week 12 to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Dyspnea Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Dyspnea Score-0.3 ± 7.60.9 ± 16.4
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.861 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.768 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.678 (Significance threshold of 0.05.) · Mean difference (net): 1.16 · 95% CI -4.33 to 6.64Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.695 (Significance threshold of 0.05.) · Mean difference (net): 1.06 · 95% CI -4.24 to 6.36Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Cough Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Cough Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Cough Score8.0 ± 16.7-0.4 ± 12.3
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.056 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.067 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.083 (Significance threshold of 0.05.) · Mean difference (net): -8.33 · 95% CI -17.76 to 1.10Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.075 (Significance threshold of 0.05.) · Mean difference (net): -8.6 · 95% CI -18.09 to 0.89Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Cough Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Cough Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Cough Score-1.3 ± 17-2.9 ± 18.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.744 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.775 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.746 (Significance threshold of 0.05.) · Mean difference (net): -1.59 · 95% CI -11.25 to 8.07Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.696 (Significance threshold of 0.05.) · Mean difference (net): -1.94 · 95% CI -11.7 to 7.82Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Energy Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Energy Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Energy Score-0.6 ± 11.8-3.1 ± 12.2
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.527 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.482
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.523 (Significance threshold of 0.05.) · Mean difference (net): -2.56 · 95% CI -10.44 to 5.33Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.435 (Significance threshold of 0.05.) · Mean difference (net): -3.1 · 95% CI -10.93 to 4.72Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Energy Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Energy Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Energy Score3.9 ± 11.1-2.8 ± 11.7
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.068 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.066 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.105 (Significance threshold of 0.05.) · Mean difference (net): -6.68 · 95% CI -14.75 to 1.40Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.079 (Significance threshold of 0.05.) · Mean difference (net): -7.2 · 95% CI -15.25 to 0.85Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Symptoms Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Symptoms Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Symptoms Score2.7 ± 9.8-0.5 ± 9.2
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.225 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.278 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.291 (Significance threshold of 0.05.) · Mean difference (net): -3.15 · 95% CI -9.01 to 2.72Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.213 (Significance threshold of 0.05.) · Mean difference (net): -3.71 · 95% CI -9.55 to 2.14Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Symptoms Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Symptoms Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Symptoms Score1.0 ± 8.3-1.0 ± 12.0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.107 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.546 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.529 (Significance threshold of 0.05.) · Mean difference (net): -1.92 · 95% CI -7.93 to 4.08Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.413 (Significance threshold of 0.05.) · Mean difference (net): -2.50 · 95% CI -8.52 to 3.51Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Impacts Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Impacts Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Impacts Score-0.04 ± 0.11-0.04 ± 0.15
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.791 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.880 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.879 (Significance threshold of 0.05.) · Mean difference (net): -0.01 · 95% CI -0.08 to 0.07Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.790 (Significance threshold of 0.05.) · Mean difference (net): -0.01 · 95% CI -0.09 to 0.07Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Living With Pulmonary Fibrosis Impacts Score

The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · score on a scale
Change in Living With Pulmonary Fibrosis Impacts Score
score on a scalePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Living With Pulmonary Fibrosis Impacts Score-0.02 ± 0.13-0.05 ± 0.16
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.404 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.517 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.471 (Significance threshold of 0.05.) · Mean difference (net): -0.03 · 95% CI -0.11 to 0.05Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.420 (Significance threshold of 0.05.) · Mean difference (net): -0.03 · 95% CI -0.11 to 0.05Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryChange in Immunosuppressive (IS) Regimen

Percentage of patients requiring an increased dose or a change in their glucocorticoid (GC) / immunosuppression (IS) agent for clinical worsening/flare of MA-ILD

Time frame:
Baseline (Week 0) to week 12
Reported as:
Count of participants · Participants
Change in Immunosuppressive (IS) Regimen
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Immunosuppressive (IS) Regimen02
SecondaryAbsolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks

FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · mL
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks
mLPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks-30.5 ± 235.616.7 ± 199.9
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.693 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.513 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.479 (Significance threshold of 0.05.) · Mean difference (net): 47 · 95% CI -87 to 181Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.378 (Significance threshold of 0.05.) · Mean difference (net): 58 · 95% CI -74 to 190Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryRelative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks

FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · percent change
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks-0.7 ± 8.90.6 ± 8.1
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.838 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.635 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.628 (Significance threshold of 0.05.) · Mean difference (net): 1.3 · 95% CI -4.2 to 6.8Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.552 (Significance threshold of 0.05.) · Mean difference (net): 1.6 · 95% CI -3.8 to 6.9Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryAbsolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · mL
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks
mLPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks-37.3 ± 210.79 ± 156.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.537 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.428 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.466 (Significance threshold of 0.05.) · Mean difference (net): 46 · 95% CI -81 to 174Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.353 (Significance threshold of 0.05.) · Mean difference (net): 59 · 95% CI -68 to 186Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryRelative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · percent change
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks-0.8 ± 8.30.4 ± 8.0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.687 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.637 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.645 (Significance threshold of 0.05.) · Mean difference (net): 1.2 · 95% CI -4.0 to 6.4Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.555 (Significance threshold of 0.05.) · Mean difference (net): 1.5 · 95% CI -3.6 to 6.6Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · % of healthy standard
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12-0.7 ± 6.20.7 ± 5.1
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.682 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.458 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.441 (Significance threshold of 0.05.) · Mean difference (net): 1.4 · 95% CI -2.2 to 5Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.346 (Significance threshold of 0.05.) · Mean difference (net): 1.7 · 95% CI -1.9 to 5.2Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · percent change
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12-0.5 ± 8.90.8 ± 8.1
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.861 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.702 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.638 (Significance threshold of 0.05.) · Mean difference (net): 1.3 · 95% CI -4.2 to 6.8Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.559 (Significance threshold of 0.05.) · Mean difference (net): 1.6 · 95% CI -3.8 to 6.9Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · % of healthy standard
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24-0.6 ± 5.70.7 ± 4.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.562 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.443 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.460 (Significance threshold of 0.05.) · Mean difference (net): 1.3 · 95% CI -2.2 to 4.7Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.361 (Significance threshold of 0.05.) · Mean difference (net): 1.5 · 95% CI -1.8 to 4.9Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · percent change
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24-0.4 ± 8.30.8 ± 8.0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.669 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.647 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.654 (Significance threshold of 0.05.) · Mean difference (net): 1.2 · 95% CI -4.1 to 6.4Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.562 (Significance threshold of 0.05.) · Mean difference (net): 1.5 · 95% CI -3.7 to 6.6Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
SecondaryPercentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Declined ≥5%43
Declined ≥7.5%42
Declined ≥10%12
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.791 (Decline ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.453 (Decline ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.486 (Decline ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Declined ≥5%53
Declined ≥7.5%42
Declined ≥10%31
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.524 (Decline ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.449 (Decline ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.341 (Decline ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Decline ≥5%43
Decline ≥7.5%42
Decline ≥10%12
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.791 (Decline ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.453 (Decline ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.486
SecondaryPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Decline ≥5%53
Decline ≥7.5%42
Decline ≥10%21
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.524 (Decline ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.449 (Decline ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.607 (Decline ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 12

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 12
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Stable1111
Improved ≥5%54
Improved ≥7.5%43
Improved ≥10%22
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.703 (Stable. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.841 (Improve ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.791 (Improve ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.911 (Improve ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 24

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 24
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Stable1010
Improved ≥5%77
Improved ≥7.5%24
Improved ≥10%11
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.768 (Stable. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.827 (Improve ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.313 (Improve ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.945 (Improve ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 12

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 12
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Stable1111
Improved ≥5%54
Improved ≥7.5%44
Improved ≥10%32
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.703 (Stable. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.841 (Improve ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.867 (Improve ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.723 (Improve ≥10%. Significance threshold of 0.05.)
SecondaryPercentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 24

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 24
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Stable1010
Improved ≥5%77
Improved ≥7.5%35
Improved ≥10%11
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.768 (Stable. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.827 (Improve ≥5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.349 (Improve ≥7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.945 (Improve ≥10%. Significance threshold of 0.05.)
SecondaryTime to FVC (mL) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)

FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.

Time frame:
Baseline (week 0) to 24 weeks
Reported as:
Mean · Weeks
Time to FVC (mL) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)
WeeksPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
5% Improvement17.7 ± 6.218.7 ± 6.6
7.5% Improvement14.8 ± 5.218.8 ± 6.7
10% Improvement16.3 ± 6.715.7 ± 7.1
5% Decline17.9 ± 6.414.9 ± 6
7.5% Decline17.1 ± 6.412 ± 0
10% Decline20.0 ± 6.912 ± 0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.728 (Improve 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.741 (Improve 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.426 (Improve 5%. Significance threshold of 0.05.) · Hazard ratio (hr): 1.52 · 95% CI 0.54 to 4.22Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.937 (Improve 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.290 (Improve 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.306 (Improve 7.5%. Significance threshold of 0.05.) · Hazard ratio (hr): 1.94 · 95% CI 0.55 to 6.88Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.423 (Improve 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.918 (Improve 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.694 (Improve 10%. Significance threshold of 0.05.) · Hazard ratio (hr): 1.46 · 95% CI 0.23 to 9.40Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.405 (Decline 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.446 (Decline 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.273 (Decline 5%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.49 · 95% CI 0.14 to 1.76Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.467 (Decline 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.317 (Decline 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.068 (Decline 7.5%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.18 · 95% CI 0.03 to 1.14Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.388 (Decline 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.219 (Decline 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.201 (Decline 10%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.13 · 95% CI 0.01 to 3.00Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
SecondaryTime to FVC (%) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)

FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.

Time frame:
Baseline (week 0) to 24 weeks
Reported as:
Mean · Weeks
Time to FVC (%) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)
WeeksPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
5% Improvement17.7 ± 6.218.7 ± 6.6
7.5% Improvement16.2 ± 5.818.7 ± 6.6
10% Improvement15.3 ± 5.815.7 ± 7.1
5% Decline17.9 ± 6.414.9 ± 6
7.5% Decline17.1 ± 6.412 ± 0
10% Decline18.1 ± 8.612 ± 0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.728 (Improve 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.741 (Improve 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.426 (Improve 5%. Significance threshold of 0.05.) · Hazard ratio (hr): 1.52 · 95% CI 0.54 to 4.22Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.908 (Improve 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.477 (Improve 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.231 (Improve 7.5%. Significance threshold of 0.05.) · Hazard ratio (hr): 2.01 · 95% CI 0.64 to 6.27Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.411 (Improve 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.935 (Improve 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.951 (Improve 10%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.95 · 95% CI 0.18 to 5.13Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.405 (Decline 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.446 (Decline 5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.273 (Decline 5%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.49 · 95% CI 0.14 to 1.76Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.467 (Decline 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.317 (Decline 7.5%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.068 (Decline 7.5%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.18 · 95% CI 0.03 to 1.14Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.651 (Decline 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.423 (Decline 10%. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.384 (Decline 10%. Significance threshold of 0.05.) · Hazard ratio (hr): 0.18 · 95% CI 0 to 8.43Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
SecondaryTime to Progression

Defined as either time for event a, b or c. Event a. ≥ 10% decline in FVC (mL) or death or transplant. Event b. ILD worsening definition (per protocol) or death or transplant. Event c. non-elective hospitalization for ILD worsening/flare or death or lung transplant.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · Weeks
Time to Progression
WeeksPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Time to Progression15.2 ± 9.815.8 ± 5.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 1.00 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.913 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Regression, Cox · p = 0.457 (Significance threshold of 0.05.) · Hazard ratio (hr): 0.59 · 95% CI 0.14 to 2.40Estimation parameter is the hazard in Nintedanib arm / hazard in Placebo arm.
Other pre-specifiedValidity of Forced Vital Capacity (FVC) in ml Measured by Home Spirometry

Validity of FVC (mL) by home spirometry is measured as intraclass correlation coefficient with FVC (mL) obtained by gold standard clinic spirometry. Unsupervised home spirometry values taken +/- 7 days from the in-clinic spirometry dates were averaged to calculate observational values.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · mL
Validity of Forced Vital Capacity (FVC) in ml Measured by Home Spirometry
mLIn-Clinic SpirometrySupervised Home SpirometryUnsupervised Home Spirometry
FVC (mL) at baseline2481 ± 8412489 ± 8192577 ± 848
FVC (mL) at Week 122507 ± 8872448 ± 8812493 ± 898
FVC (mL) at Week 242465 ± 8512535 ± 8722449 ± 877
Statistical analysis
  • In-Clinic Spirometry vs Supervised Home Spirometry · Intraclass correlation coefficient: 0.909
  • In-Clinic Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.917
  • Supervised Home Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.918
  • In-Clinic Spirometry vs Supervised Home Spirometry · Intraclass correlation coefficient: 0.969
  • In-Clinic Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.967
  • Supervised Home Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.988
  • In-Clinic Spirometry vs Supervised Home Spirometry · Intraclass correlation coefficient: 0.975
  • In-Clinic Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.975
  • Supervised Home Spirometry vs Unsupervised Home Spirometry · Intraclass correlation coefficient: 0.989
Other pre-specifiedReliability of Forced Vital Capacity (FVC) in mL by Home Spirometry

Reliability of FVC (mL) by home spirometry is measured as spearman correlation with FVC (mL) of test (baseline) and re-test (Week 12). Unsupervised home spirometry values taken +/- 7 days from the test and re-test dates were averaged to calculate observational values.

Time frame:
Baseline (week 0) to week 12
Reported as:
Median · mL
Reliability of Forced Vital Capacity (FVC) in mL by Home Spirometry
mLSupervised Home SpirometryUnsupervised Home Spirometry
FVC (mL) at baseline2330 (1960 to 2910)2295 (2020 to 2925)
FVC (mL) at Week 122230 (1915 to 2975)2190 (1850 to 3020)
Statistical analysis
  • Supervised Home Spirometry · t-test, 2 sided · p = <0.001 (No multiple comparisons adjustment. P\<0.05 considered significant.) · Spearman correlation coefficient: 0.948
  • Unsupervised Home Spirometry · t-test, 2 sided · p = <0.001 (No multiple comparisons adjustment. P\<0.05 considered significant.) · Spearman correlation coefficient: 0.950
Other pre-specifiedAbsolute Change in DLCO(%) From Baseline to 12 Weeks

DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · % of healthy standard
Absolute Change in DLCO(%) From Baseline to 12 Weeks
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in DLCO(%) From Baseline to 12 Weeks1.6 ± 20.50.3 ± 7.6
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.633 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.816 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.830 (Significance threshold of 0.05.) · Mean difference (net): -1.3 · 95% CI -13.2 to 10.6Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.950 (Significance threshold of 0.05.) · Mean difference (net): 0.4 · 95% CI -11.3 to 12.0Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in DLCO(%) From Baseline to 12 Weeks

DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · percent change
Relative Change in DLCO(%) From Baseline to 12 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in DLCO(%) From Baseline to 12 Weeks5.2 ± 23.31.6 ± 18.0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.611 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.615 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.649 (Significance threshold of 0.05.) · Mean difference (net): -3.6 · 95% CI -19.5 to 12.3Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.888 (Significance threshold of 0.05.) · Mean difference (net): -1.1 · 95% CI -16.7 to 14.5Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedAbsolute Change in DLCO(%) From Baseline to 24 Weeks

DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · % of healthy standard
Absolute Change in DLCO(%) From Baseline to 24 Weeks
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in DLCO(%) From Baseline to 24 Weeks3.7 ± 23.1-2.4 ± 11.5
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.900 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.290 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.263 (Significance threshold of 0.05.) · Mean difference (net): -6.1 · 95% CI -17.1 to 4.8Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.482 (Significance threshold of 0.05.) · Mean difference (net): -3.8 · 95% CI -14.7 to 7.1Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in DLCO(%) From Baseline to 24 Weeks

DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · percent change
Relative Change in DLCO(%) From Baseline to 24 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in DLCO(%) From Baseline to 24 Weeks6.3 ± 29.6-2.9 ± 18.9
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.632 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.242 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.210 (Significance threshold of 0.05.) · Mean difference (net): -9.2 · 95% CI -23.9 to 5.4Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.402 (Significance threshold of 0.05.) · Mean difference (net): -6.1 · 95% CI -20.7 to 8.5Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedAbsolute Change in FEV1(mL) From Baseline to 12 Weeks

FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · mL
Absolute Change in FEV1(mL) From Baseline to 12 Weeks
mLPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in FEV1(mL) From Baseline to 12 Weeks-104.0 ± 305.1-21.1 ± 163.1
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.884 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.311 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.250 (Significance threshold of 0.05.) · Mean difference (net): 83 · 95% CI -60 to 227Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.187 (Significance threshold of 0.05.) · Mean difference (net): 98 · 95% CI -50 to 246Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in FEV1(mL) From Baseline to 12 Weeks

FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · percent change
Relative Change in FEV1(mL) From Baseline to 12 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in FEV1(mL) From Baseline to 12 Weeks-4.2 ± 12.6-1.3 ± 7.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.930 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.404 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.368 (Significance threshold of 0.05.) · Mean difference (net): 2.9 · 95% CI -3.6 to 9.4Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.315 (Significance threshold of 0.05.) · Mean difference (net): 3.3 · 95% CI -3.3 to 10.0Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedAbsolute Change in FEV1(mL) From Baseline to 24 Weeks

FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · mL
Absolute Change in FEV1(mL) From Baseline to 24 Weeks
mLPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in FEV1(mL) From Baseline to 24 Weeks-113.2 ± 229.6-49.5 ± 122
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.496 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.276 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.351 (Significance threshold of 0.05.) · Mean difference (net): 64 · 95% CI -73 to 200Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.256 (Significance threshold of 0.05.) · Mean difference (net): 81 · 95% CI -61 to 223Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in FEV1(mL) From Baseline to 24 Weeks

FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · percent change
Relative Change in FEV1(mL) From Baseline to 24 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in FEV1(mL) From Baseline to 24 Weeks-4.5 ± 9.8-2.9 ± 8.2
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.580 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.572 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.603 (Significance threshold of 0.05.) · Mean difference (net): 1.6 · 95% CI -4.6 to 7.8Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.502 (Significance threshold of 0.05.) · Mean difference (net): 2.1 · 95% CI -4.3 to 8.5Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedAbsolute Change in FEV1(%) From Baseline to 12 Weeks

FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · % of healthy standard
Absolute Change in FEV1(%) From Baseline to 12 Weeks
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in FEV1(%) From Baseline to 12 Weeks-3.4 ± 9.6-0.5 ± 5.0
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.884 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.253 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.208 (Significance threshold of 0.05.) · Mean difference (net): 2.9 · 95% CI -1.7 to 7.6Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.167 (Significance threshold of 0.05.) · Mean difference (net): 3.3 · 95% CI -1.5 to 8.1Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in FEV1(%) From Baseline to 12 Weeks

FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 12
Reported as:
Mean · percent change
Relative Change in FEV1(%) From Baseline to 12 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in FEV1(%) From Baseline to 12 Weeks-3.9 ± 12.7-1.0 ± 7.8
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.953 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.409 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.374 (Significance threshold of 0.05.) · Mean difference (net): 2.9 · 95% CI -3.6 to 9.4Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.319 (Significance threshold of 0.05.) · Mean difference (net): 3.3 · 95% CI -3.4 to 10.0Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedAbsolute Change in FEV1(%) From Baseline to 24 Weeks

FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · % of healthy standard
Absolute Change in FEV1(%) From Baseline to 24 Weeks
% of healthy standardPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Absolute Change in FEV1(%) From Baseline to 24 Weeks-3.2 ± 7.5-1.3 ± 4.7
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.465 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.335 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.388 (Significance threshold of 0.05.) · Mean difference (net): 1.9 · 95% CI -2.5 to 6.3Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.302 (Significance threshold of 0.05.) · Mean difference (net): 2.4 · 95% CI -2.2 to 7Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedRelative Change in FEV1(%) From Baseline to 24 Weeks

FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.

Time frame:
Baseline (week 0) to week 24
Reported as:
Mean · percent change
Relative Change in FEV1(%) From Baseline to 24 Weeks
percent changePlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Relative Change in FEV1(%) From Baseline to 24 Weeks-4.0 ± 9.9-2.4 ± 8.2
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.597 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.579 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.608 (Significance threshold of 0.05.) · Mean difference (net): 1.6 · 95% CI -4.6 to 7.8Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Mixed Models Analysis · p = 0.505 (Significance threshold of 0.05.) · Mean difference (net): 2.1 · 95% CI -4.3 to 8.5Estimation parameter is the change in Nintedanib arm - change in Placebo arm.
Other pre-specifiedProgression Free Survival

Connective Tissue Disease (CTD)-ILD outcome as per Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT), which is defined as the occurrence of any of the following: death, lung transplant, FVC ≥10% decline, or FVC ≥5% decline with DLCO ≥15% decline. Clinical worsening is defined as death, lung transplant, new/worsening O2 requirement at rest (\>2L), non-elective hospitalization for ILD clinical worsening/flare, ILD worsening definition (per protocol), or out of protocol rescue medication for ILD clinical worsening/flare.

Time frame:
Weeks 12 and 24
Reported as:
Count of participants · Participants
Progression Free Survival
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Week 121815
Week 241716
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.544 (Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.83 (Week 24. Significance threshold of 0.05.)
Other pre-specifiedSteroid Use (Calculated Using Prednisone Dose Equivalents)

Change of steroid dosage (mg/day) from baseline to follow up.

Time frame:
Weeks 12 and 24
Reported as:
Mean · mg/day
Steroid Use (Calculated Using Prednisone Dose Equivalents)
mg/dayPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Week 120 ± 1.281.72 ± 7.93
Week 244.34 ± 15.110.99 ± 7.73
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.843 (Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.322 (Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.423 (Week 24. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.378 (Week 24. Significance threshold of 0.05.)
Other pre-specifiedChange in Supplemental Oxygen Needs From Baseline to Week 12

Change in supplemental oxygen requirement (L) from baseline to follow up.

Time frame:
Baseline (week 0) to 12 weeks
Reported as:
Mean · L
Change in Supplemental Oxygen Needs From Baseline to Week 12
LPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Supplemental Oxygen Needs From Baseline to Week 120 ± 0.10 ± 0.6
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 1.00 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.849 (Significance threshold of 0.05.)
Other pre-specifiedChange in Supplemental Oxygen Needs From Baseline to Week 24

Change in supplemental oxygen requirement (L) from baseline to follow up.

Time frame:
Baseline (week 0) to 24 weeks
Reported as:
Mean · L
Change in Supplemental Oxygen Needs From Baseline to Week 24
LPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Change in Supplemental Oxygen Needs From Baseline to Week 240 ± 0.1-0.2 ± 0.6
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.087 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.084 (Significance threshold of 0.05.)
Other pre-specifiedPatient Assessment of Change

Patient Assessment of Change (also known as Patient Global Impression of Change): Overall Assessment of Change by Patient. Patient overall assessment of change in disease status from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.

Time frame:
Weeks 12 and 24
Reported as:
Count of participants · Participants
Patient Assessment of Change
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Week 12 — Major improvement00
Week 12 — Moderate improvement14
Week 12 — Minimal improvement37
Week 12 — No change148
Week 12 — Minimal worsening32
Week 12 — Moderate worsening11
Week 12 — Major worsening00
Week 24 — Major improvement00
Week 24 — Moderate improvement15
Week 24 — Minimal improvement67
Week 24 — No change87
Week 24 — Minimal worsening61
Week 24 — Moderate worsening00
Week 24 — Major worsening10
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.264 (Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.121 (Week 24. Significance threshold of 0.05.)
Other pre-specifiedPhysician Assessment of Change

Physician's overall assessment of change in disease status of the patient from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.

Time frame:
Weeks 12 and 24
Reported as:
Count of participants · Participants
Physician Assessment of Change
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Disease activity at Week 12 — Major improvement00
Disease activity at Week 12 — Moderate improvement11
Disease activity at Week 12 — Minimal improvement25
Disease activity at Week 12 — No change1413
Disease activity at Week 12 — Minimal worsening33
Disease activity at Week 12 — Moderate worsening10
Disease activity at Week 12 — Major worsening00
Disease activity at Week 24 — Major improvement00
Disease activity at Week 24 — Moderate improvement01
Disease activity at Week 24 — Minimal improvement45
Disease activity at Week 24 — No change1312
Disease activity at Week 24 — Minimal worsening41
Disease activity at Week 24 — Moderate worsening00
Disease activity at Week 24 — Major worsening10
Disease damage at Week 12 — Major improvement00
Disease damage at Week 12 — Moderate improvement00
Disease damage at Week 12 — Minimal improvement10
Disease damage at Week 12 — No change1921
Disease damage at Week 12 — Minimal worsening11
Disease damage at Week 12 — Moderate worsening00
Disease damage at Week 12 — Major worsening00
Disease damage at week 24 — Major improvement00
Disease damage at week 24 — Moderate improvement00
Disease damage at week 24 — Minimal improvement02
Disease damage at week 24 — No change2116
Disease damage at week 24 — Minimal worsening11
Disease damage at week 24 — Moderate worsening00
Disease damage at week 24 — Major worsening00
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.681 (Disease activity at Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.441 (Disease activity at Week 24. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.584 (Disease damage at Week 12. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.291 (Disease damage at Week 24. Null hypothesis: Proportion in Nintedanib arm = Proportion in Placebo arm.)
Other pre-specifiedChanges in Sit to Stand Test From Baseline to Week 12

Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.

Time frame:
Baseline (week 0) to 12 weeks
Reported as:
Mean · Reps
Changes in Sit to Stand Test From Baseline to Week 12
RepsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Changes in Sit to Stand Test From Baseline to Week 120.1 ± 1.40.4 ± 3.7
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.564 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.767 (Significance threshold of 0.05.)
Other pre-specifiedChanges in Sit to Stand Test From Baseline to Week 24

Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.

Time frame:
Baseline (week 0) to 24 weeks
Reported as:
Mean · Reps
Changes in Sit to Stand Test From Baseline to Week 24
RepsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Changes in Sit to Stand Test From Baseline to Week 240.3 ± 1.91.4 ± 2.7
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.151 (Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · t-test, 2 sided · p = 0.149 (Significance threshold of 0.05.)
Other pre-specifiedChange in High-Resolution Computed Tomography (HRCT) Chest From Baseline

HRCT patterns will be analyzed using semi-quantitative and quantitative image based scoring to summarize an image as normal or abnormal. Change of summary status from baseline to follow up. Patterns include: Ground glass, Consolidation / Air Space, Mixed GGO/AS, Parenchymal Micronodules, Reticular Opacities, Linear Opacities or Septal Lines, Peribronchovascular Thickening, Honeycombing, and Traction Bronchiectasis.

Time frame:
Baseline (week 0) to 24 weeks
Reported as:
Count of participants · Participants
Change in High-Resolution Computed Tomography (HRCT) Chest From Baseline
ParticipantsPlacebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of Care
Ground glass — Normal to normal00
Ground glass — Normal to abnormal10
Ground glass — Abnormal to normal00
Ground glass — Abnormal to abnormal2118
Consolidation / Air Space — Normal to normal1511
Consolidation / Air Space — Normal to abnormal40
Consolidation / Air Space — Abnormal to normal12
Consolidation / Air Space — Abnormal to abnormal25
Mixed GGO/AS — Normal to normal1912
Mixed GGO/AS — Normal to abnormal10
Mixed GGO/AS — Abnormal to normal02
Mixed GGO/AS — Abnormal to abnormal24
Parenchymal Micronodules — Normal to normal2013
Parenchymal Micronodules — Normal to abnormal11
Parenchymal Micronodules — Abnormal to normal01
Parenchymal Micronodules — Abnormal to abnormal13
Reticular Opacities — Normal to normal11
Reticular Opacities — Normal to abnormal11
Reticular Opacities — Abnormal to normal10
Reticular Opacities — Abnormal to abnormal1916
Linear Opacities or Septal Lines — Normal to normal01
Linear Opacities or Septal Lines — Normal to abnormal10
Linear Opacities or Septal Lines — Abnormal to normal00
Linear Opacities or Septal Lines — Abnormal to abnormal2117
Peribronchovascular Thickening — Normal to normal129
Peribronchovascular Thickening — Normal to abnormal22
Peribronchovascular Thickening — Abnormal to normal44
Peribronchovascular Thickening — Abnormal to abnormal43
Honeycombing — Normal to normal1610
Honeycombing — Normal to abnormal01
Honeycombing — Abnormal to normal00
Honeycombing — Abnormal to abnormal67
Traction Bronchiectasis — Normal to normal01
Traction Bronchiectasis — Normal to abnormal10
Traction Bronchiectasis — Abnormal to normal00
Traction Bronchiectasis — Abnormal to abnormal2117
Statistical analysis
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.36 (Ground Glass. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.117 (Consolidation/Air Space. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.18 (Mixed GGO/AS. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.374 (Parenchymal Micronodules. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.834 (Reticular Opacities. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.36 (Linear Opacities or Septal Lines. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.982 (Peribronchovascular Thickening. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.353 (Honeycombing. Significance threshold of 0.05.)
  • Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care vs Nintedanib Plus Standard of Care · Chi-squared · p = 0.36 (Traction Bronchiectasis. Significance threshold of 0.05.)
Other pre-specifiedAdverse Events (AEs) and Tolerance

All AEs and tolerance event will be compared between treatment arms * Percentage of subjects who discontinue study drug * Patients with any AEs * Patients with Serious Adverse Event (SAE)s (includes patient with AE of special interest) * Patients with AEs of special interest (gastrointestinal perforation and hepatic injury)

Time frame:
Baseline (week 0) to week 24 plus 28 day follow-up
Reported as:
Count of participants · Participants
Adverse Events (AEs) and Tolerance
ParticipantsExperimental Phase: Placebo Plus Standard of CareExperimental Phase: Nintedanib Plus Standard of CareOpen Label Phase: Nintedanib Plus Standard of Care
Discontinued study drug468
Any Adverse Event162136
Serious Adverse Event065
Adverse Event of special interest010
Statistical analysis
  • Experimental Phase: Placebo Plus Standard of Care vs Experimental Phase: Nintedanib Plus Standard of Care · Chi-squared · p = 0.928 (Discontinued study drug. Significance threshold of 0.05.)
  • Experimental Phase: Placebo Plus Standard of Care vs Experimental Phase: Nintedanib Plus Standard of Care · Chi-squared · p = 0.322 (Any adverse event. Significance threshold of 0.05.)
  • Experimental Phase: Placebo Plus Standard of Care vs Experimental Phase: Nintedanib Plus Standard of Care · Chi-squared · p = 0.178 (Serious Adverse Event. Significance threshold of 0.05.)
  • Experimental Phase: Placebo Plus Standard of Care vs Experimental Phase: Nintedanib Plus Standard of Care · Chi-squared · p = 0.322 (Adverse Event of special interest. Significance threshold of 0.05.)
Other pre-specifiedRate of Patient Recruitment, Enrollment, Screen Failure, and Dropout Rates Between the Local Sites and the Remote Site of Physician Referred Patients.

Compare the participant recruitment, enrollment, screen failure and drop out rates between participants recruited through local clinical trial site vs. remote clinical trial site physician referrals. Not all participants were enrolled, and not all participants were physician referrals. 57 of 62 enrolled participants were physician referrals. 44 of 49 randomized participants were physician referrals.

Time frame:
Patient recruitment to randomization. Median of 51 days from recruitment to randomization. Randomization occurred at baseline.
Reported as:
Count of participants · Participants
Rate of Patient Recruitment, Enrollment, Screen Failure, and Dropout Rates Between the Local Sites and the Remote Site of Physician Referred Patients.
ParticipantsLocal Physician ReferredRemote Physician Referred
Pre-screened2476
Screened (enrolled)2037
Randomized1628

Adverse events

Collected over Baseline (Week 0) to end of study (Week 24) plus 28 day follow-up. 28 week observation period total.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Phase: Nintedanib Plus Standard of Care0/25 (0%)6/25 (24%)21/25 (84%)
Experimental Phase: Placebo Plus Standard of Care0/24 (0%)0/24 (0%)16/24 (66.7%)
Open Label Phase: Nintedanib Plus Standard of Care0/44 (0%)5/44 (11.4%)36/44 (81.8%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventExperimental Phase: Nintedanib Plus Standard of CareExperimental Phase: Placebo Plus Standard of CareOpen Label Phase: Nintedanib Plus Standard of Care
Hepatic enzyme increasedHepatobiliary disorders1/250/240/44
HysterectomyReproductive system and breast disorders1/250/240/44
MigraineNervous system disorders1/250/240/44
Mild heart attackCardiac disorders1/250/240/44
Renal calculiRenal and urinary disorders1/250/240/44
Right renal artery stenosisRenal and urinary disorders1/250/240/44
Soft tissue infectionInfections and infestations1/250/240/44
Brain AneurysmVascular disorders0/250/241/44
Eye infectionInfections and infestations0/250/241/44
PancytopeniaBlood and lymphatic system disorders0/250/241/44
Most frequent other events
Showing 10 of 45
Most frequent other events
EventExperimental Phase: Nintedanib Plus Standard of CareExperimental Phase: Placebo Plus Standard of CareOpen Label Phase: Nintedanib Plus Standard of Care
DiarrheaGastrointestinal disorders12/255/248/44
DyspneaRespiratory, thoracic and mediastinal disorders1/254/241/44
NauseaGastrointestinal disorders3/252/242/44
Weight lossMetabolism and nutrition disorders3/250/242/44
VomitingGastrointestinal disorders1/252/241/44
CoughRespiratory, thoracic and mediastinal disorders1/252/242/44
Upper respiratory InfectionInfections and infestations1/251/243/44
DyspepsiaGastrointestinal disorders0/250/242/44
Gastrointestinal PainGastrointestinal disorders1/250/242/44
FatigueGeneral disorders0/250/242/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
<=18 years000
Between 18 and 65 years171330
>=65 years71219
Age, Continuous
Age, Continuous(years)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
Median57 (48.5 to 66)62 (50 to 68)58 (49 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
Female181533
Male61016
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
Hispanic or Latino044
Not Hispanic or Latino242145
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American279
White211334
More than one race000
Unknown or Not Reported022
Region of Enrollment
Region of Enrollment(participants)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
United States242549
BMI, Continuous
BMI, Continuous(kilograms / meters squared)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
Median29.6 (27 to 33.8)28.5 (23.4 to 37.5)29.1 (25.5 to 34.9)
Predicted FVC%, Continuous
Predicted FVC%, Continuous(percent)Placebo Plus Standard of Care, Then Nintedanib Plus Standard of CareNintedanib Plus Standard of CareTotal
Median67.7 (62.3 to 75.7)58.2 (54.4 to 71.2)64.4 (57.9 to 74)
08

Study locations

10 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Northwell Health
    New York, New York 11021, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15216, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84112, United States
09

References and documents

Publications

  • Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. PubMed 31112379 ↗
  • Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PubMed 31566307 ↗
  • Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2021 Dec 9;13:1759720X211060907. doi: 10.1177/1759720X211060907. eCollection 2021. PubMed 34917177 ↗
  • Shen L, Yan Q, Chen X. Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Arch Rheumatol. 2019 Aug 26;35(2):180-188. doi: 10.46497/ArchRheumatol.2020.7381. eCollection 2020 Jun. PubMed 32851366 ↗
  • Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016 Sep 12;6:33226. doi: 10.1038/srep33226. PubMed 27615411 ↗
  • Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1. PubMed 25729034 ↗
  • Liang J, Cao H, Yang Y, Ke Y, Yu Y, Sun C, Yue L, Lin J. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med (Lausanne). 2021 Feb 3;8:626953. doi: 10.3389/fmed.2021.626953. eCollection 2021. PubMed 33614683 ↗
  • Aggarwal R, Oddis CV, Sullivan DI, Moghadam-Kia S, Saygin D, Kass DJ, Koontz DC, Li P, Conoscenti CS, Olson AL; MINT investigators. Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease. BMC Pulm Med. 2024 Oct 30;24(1):544. doi: 10.1186/s12890-024-03314-0. PubMed 39478532 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Sharing of individual participant data will require written approval from sponsor and steering committee.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data requests will not be accepted prior to final publication of the trial.

Access criteria: All data requests will require written approval from sponsor and steering committee prior to release of data

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Mar 2025, 19 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion. A results delay was requested in Feb 2026.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Apr 5, 2023
StartActual
Aug 1, 2023
Primary completionActual
Mar 17, 2025
CompletionActual
Dec 31, 2025
Results delay requested
Feb 3, 2026
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Enrollment
49→62
Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Living withWith Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea scoreScoreTime frame: Baseline (week 0) to 12 weeks → Baseline (week 0) to week 12
Oct 15, 2026
Documents
Secondary outcomes
16 edited, 14 added, 31 more
What changed in the outcomes
  • EditedChange in Living withWith Pulmonary Fibrosis Dyspnea scoreScoreTime frame: Baseline (week 0) to week 24
  • EditedChange in other Living withWith Pulmonary Fibrosis scoresDyspnea ScoreTime frame: Week 12 to week 24
  • EditedChange in immunosuppressiveImmunosuppressive (IS) regimenRegimenTime frame: Baseline (Week 0) to week 12
  • EditedAbsolute and relative changeChange in Forced Vital Capacity (FVC) (mL) from baselineFrom Baseline to 12 weeksWeeksTime frame: Baseline (week 0) to week 12
  • EditedAbsolute and relative changeRelative Change in Forced Vital Capacity (FVC) (mL) from baselineFrom Baseline to 24 weeks12 WeeksTime frame: Baseline (week 0) to week 24 → Baseline (week 0) to week 12
  • EditedAbsolute and relative changeChange in Forced Vital Capacity (FVC) (%mL) from baselineFrom Baseline to week 1224 WeeksTime frame: Baseline (week 0) to week 12 → Baseline (week 0) to week 24
  • EditedAbsolute and relative changeRelative Change in Forced Vital Capacity (FVC) (%mL) from baselineFrom Baseline to week 2424 WeeksTime frame: Baseline (week 0) to week 24
  • EditedProportionPercentage of patients withPatients With a relative decline from baselineRelative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Weeks 12 and 24 → Week 12
  • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baselineFrom Baseline to weekWeek 12Time frame: baseline (week 0) at week 12 → Week 12
  • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baselineFrom Baseline to weekWeek 24Time frame: baseline (week 0) at week 24 → Week 24
  • EditedTime to FVC (mL) improvementImprovement and decline from baselineDecline From Baseline by (≥5%, 7.5%, 10%)Time frame: Baseline (week 0) to 24 weeks
  • EditedTime to progressionProgressionTime frame: Baseline (week 0) to week 24
  • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baselineFrom Baseline to weekWeek 12Time frame: baseline (week 0) at week 12 → Week 12
  • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baselineFrom Baseline to weekWeek 24Time frame: baseline (week 0) at week 24 → Week 24
  • EditedProportionPercentage of patients withPatients With a relative decline from baselineRelative Decline From Baseline in FVC (%mL) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Weeks 12 and 24 → Week 24
  • EditedTime to FVC (%) improvementImprovement and decline from baselineDecline From Baseline by (≥5%, 7.5%, 10%)Time frame: Baseline (week 0) to 24 weeks
  • AddedChange in Living With Pulmonary Fibrosis Cough ScoreTime frame: Baseline (week 0) to week 12
  • AddedChange in Living With Pulmonary Fibrosis Cough ScoreTime frame: Baseline (week 0) to week 24
  • AddedChange in Living With Pulmonary Fibrosis Energy ScoreTime frame: Baseline (week 0) to week 12
  • AddedChange in Living With Pulmonary Fibrosis Energy ScoreTime frame: Baseline (week 0) to week 24
  • AddedChange in Living With Pulmonary Fibrosis Symptoms ScoreTime frame: Baseline (week 0) to week 12
  • AddedChange in Living With Pulmonary Fibrosis Symptoms ScoreTime frame: Baseline (week 0) to week 24
  • AddedChange in Living With Pulmonary Fibrosis Impacts ScoreTime frame: Baseline (week 0) to week 12
  • AddedChange in Living With Pulmonary Fibrosis Impacts ScoreTime frame: Baseline (week 0) to week 24
  • AddedAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12Time frame: Baseline (week 0) to week 12
  • AddedRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12Time frame: Baseline (week 0) to week 12
  • AddedAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24Time frame: Baseline (week 0) to week 24
  • AddedRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24Time frame: Baseline (week 0) to week 24
  • AddedPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Week 12
  • AddedPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Week 24
  • …and 31 more, on the record history on ClinicalTrials.gov ↗
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Enrollment 49→62
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Living withWith Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea scoreScoreTime frame: Baseline (week 0) to 12 weeks → Baseline (week 0) to week 12
    Secondary outcomes 16 edited, 14 added, 31 more
    What changed in the outcomes
    • EditedChange in Living withWith Pulmonary Fibrosis Dyspnea scoreScoreTime frame: Baseline (week 0) to week 24
    • EditedChange in other Living withWith Pulmonary Fibrosis scoresDyspnea ScoreTime frame: Week 12 to week 24
    • EditedChange in immunosuppressiveImmunosuppressive (IS) regimenRegimenTime frame: Baseline (Week 0) to week 12
    • EditedAbsolute and relative changeChange in Forced Vital Capacity (FVC) (mL) from baselineFrom Baseline to 12 weeksWeeksTime frame: Baseline (week 0) to week 12
    • EditedAbsolute and relative changeRelative Change in Forced Vital Capacity (FVC) (mL) from baselineFrom Baseline to 24 weeks12 WeeksTime frame: Baseline (week 0) to week 24 → Baseline (week 0) to week 12
    • EditedAbsolute and relative changeChange in Forced Vital Capacity (FVC) (%mL) from baselineFrom Baseline to week 1224 WeeksTime frame: Baseline (week 0) to week 12 → Baseline (week 0) to week 24
    • EditedAbsolute and relative changeRelative Change in Forced Vital Capacity (FVC) (%mL) from baselineFrom Baseline to week 2424 WeeksTime frame: Baseline (week 0) to week 24
    • EditedProportionPercentage of patients withPatients With a relative decline from baselineRelative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Weeks 12 and 24 → Week 12
    • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baselineFrom Baseline to weekWeek 12Time frame: baseline (week 0) at week 12 → Week 12
    • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baselineFrom Baseline to weekWeek 24Time frame: baseline (week 0) at week 24 → Week 24
    • EditedTime to FVC (mL) improvementImprovement and decline from baselineDecline From Baseline by (≥5%, 7.5%, 10%)Time frame: Baseline (week 0) to 24 weeks
    • EditedTime to progressionProgressionTime frame: Baseline (week 0) to week 24
    • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baselineFrom Baseline to weekWeek 12Time frame: baseline (week 0) at week 12 → Week 12
    • EditedProportionPercentage of patients with stablePatients With Stable (+/- < 5%) or improvedImproved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baselineFrom Baseline to weekWeek 24Time frame: baseline (week 0) at week 24 → Week 24
    • EditedProportionPercentage of patients withPatients With a relative decline from baselineRelative Decline From Baseline in FVC (%mL) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Weeks 12 and 24 → Week 24
    • EditedTime to FVC (%) improvementImprovement and decline from baselineDecline From Baseline by (≥5%, 7.5%, 10%)Time frame: Baseline (week 0) to 24 weeks
    • AddedChange in Living With Pulmonary Fibrosis Cough ScoreTime frame: Baseline (week 0) to week 12
    • AddedChange in Living With Pulmonary Fibrosis Cough ScoreTime frame: Baseline (week 0) to week 24
    • AddedChange in Living With Pulmonary Fibrosis Energy ScoreTime frame: Baseline (week 0) to week 12
    • AddedChange in Living With Pulmonary Fibrosis Energy ScoreTime frame: Baseline (week 0) to week 24
    • AddedChange in Living With Pulmonary Fibrosis Symptoms ScoreTime frame: Baseline (week 0) to week 12
    • AddedChange in Living With Pulmonary Fibrosis Symptoms ScoreTime frame: Baseline (week 0) to week 24
    • AddedChange in Living With Pulmonary Fibrosis Impacts ScoreTime frame: Baseline (week 0) to week 12
    • AddedChange in Living With Pulmonary Fibrosis Impacts ScoreTime frame: Baseline (week 0) to week 24
    • AddedAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12Time frame: Baseline (week 0) to week 12
    • AddedRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12Time frame: Baseline (week 0) to week 12
    • AddedAbsolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24Time frame: Baseline (week 0) to week 24
    • AddedRelative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24Time frame: Baseline (week 0) to week 24
    • AddedPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Week 12
    • AddedPercentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%Time frame: Week 24
    • …and 31 more, on the record history on ClinicalTrials.gov ↗
    + 5 other changes: verification date, registry dates, description, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05799755
Lead sponsor
Rohit Aggarwal, MD
Responsible party
Rohit Aggarwal, MD (Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Apr 5, 2023
Start date
Aug 1, 2023
Primary completion
Mar 17, 2025
Completion
Dec 31, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Rohit Aggarwal, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion